Treatments herald a ‘new age’ for CLL

Mingling with the delegates at the first International Workshop on Chronic Lymphocytic Leukaemia to be held in the Southern Hemisphere, one soon noticed almost everyone was talking about two drugs: ibrutinib and idelalisib.

“We’re in this era of phenomenal change,” conference chairman Professor Stephen Mulligan (pictured) told Oncology Update.